128 related articles for article (PubMed ID: 18621519)
1. Use of 6-min and 12-min walking test for assessing the efficacy of formoterol in COPD.
Cazzola M; Biscione GL; Pasqua F; Crigna G; Appodia M; Cardaci V; Ferri L
Respir Med; 2008 Oct; 102(10):1425-30. PubMed ID: 18621519
[TBL] [Abstract][Full Text] [Related]
2. Energy expenditure and impact of bronchodilators in COPD patients.
Cazzola M; Segreti A; Stirpe E; Appodia M; Senis L; Matera MG
Respir Med; 2010 Oct; 104(10):1490-4. PubMed ID: 20471237
[TBL] [Abstract][Full Text] [Related]
3. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility.
Bouros D; Kottakis J; Le Gros V; Overend T; Della Cioppa G; Siafakas N
Curr Med Res Opin; 2004 May; 20(5):581-6. PubMed ID: 15140323
[TBL] [Abstract][Full Text] [Related]
4. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study.
Cote C; Pearle JL; Sharafkhaneh A; Spangenthal S
Pulm Pharmacol Ther; 2009 Feb; 22(1):44-9. PubMed ID: 19071226
[TBL] [Abstract][Full Text] [Related]
5. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD.
Worth H; Förster K; Eriksson G; Nihlén U; Peterson S; Magnussen H
Respir Med; 2010 Oct; 104(10):1450-9. PubMed ID: 20692140
[TBL] [Abstract][Full Text] [Related]
6. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
[TBL] [Abstract][Full Text] [Related]
7. Is there any difference between effects of ipratropium bromide and formoterol on exercise capacity in moderate COPD patients?
Akkoca Yildiz O; Onen ZP; Demir G; Eriş Gülbay B; Saryal S; Karabiyikoğlu G
Tuberk Toraks; 2006; 54(2):105-13. PubMed ID: 16924565
[TBL] [Abstract][Full Text] [Related]
8. Formoterol by pressurized metered-dose aerosol or dry powder on airway obstruction and lung hyperinflation in partially reversible COPD.
Brusasco V; Canonica GW; Dal Negro R; Scano G; Paggiaro P; Fabbri LM; Barisione G; D'Amato G; Varoli G; Baroffio M; Milanese M; Mereu C; Crimi E
J Aerosol Med Pulm Drug Deliv; 2011 Oct; 24(5):235-43. PubMed ID: 21689019
[TBL] [Abstract][Full Text] [Related]
9. Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD.
Molimard M; Bourcereau J; Le Gros V; Bourdeix I
Respir Med; 2005 Jun; 99(6):695-702. PubMed ID: 15878485
[TBL] [Abstract][Full Text] [Related]
10. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD.
Derom E; Strandgården K; Schelfhout V; Borgström L; Pauwels R
Respir Med; 2007 Sep; 101(9):1931-41. PubMed ID: 17544264
[TBL] [Abstract][Full Text] [Related]
11. Endurance shuttle walking test: responsiveness to salmeterol in COPD.
Brouillard C; Pepin V; Milot J; Lacasse Y; Maltais F
Eur Respir J; 2008 Mar; 31(3):579-84. PubMed ID: 18057052
[TBL] [Abstract][Full Text] [Related]
12. [Effect of ipratropium bromide on lung dynamic hyperinflation in patients with chronic obstructive lung disease].
Jorquera J; Díaz O; Lisboa C
Rev Med Chil; 2003 Jun; 131(6):605-12. PubMed ID: 12942587
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation.
Santus P; Centanni S; Verga M; Di Marco F; Matera MG; Cazzola M
Respir Med; 2006 Jul; 100(7):1277-81. PubMed ID: 16337781
[TBL] [Abstract][Full Text] [Related]
14. Improved respiratory system conductance following bronchodilator predicts reduced exertional dyspnoea.
Diba C; King GG; Berend N; Salome CM
Respir Med; 2011 Sep; 105(9):1345-51. PubMed ID: 21482091
[TBL] [Abstract][Full Text] [Related]
15. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients.
Cazzola M; Noschese P; Salzillo A; De Giglio C; D'Amato G; Matera MG
Respir Med; 2005 May; 99(5):524-8. PubMed ID: 15823447
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of procaterol on exercise dynamic lung hyperinflation during the 6-min walk test in stable patients with chronic obstructive pulmonary disease.
Satake M; Takahashi H; Sugawara K; Kawagoshi A; Tamaki A; Homma M; Morita R; Sato K; Sano M; Shioya T
Arzneimittelforschung; 2011; 61(1):8-13. PubMed ID: 21355441
[TBL] [Abstract][Full Text] [Related]
17. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
Kuna P; Jenkins M; O'Brien CD; Fahy WA
Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
[TBL] [Abstract][Full Text] [Related]
18. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial.
Bölükbas S; Eberlein M; Eckhoff J; Schirren J
Eur J Cardiothorac Surg; 2011 Jun; 39(6):995-1000. PubMed ID: 20970351
[TBL] [Abstract][Full Text] [Related]
19. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD.
Richter K; Stenglein S; Mücke M; Sieder C; Schmidtmann S; Harnest U; Weidinger G; Magnussen H
Respiration; 2006; 73(4):414-9. PubMed ID: 16534180
[TBL] [Abstract][Full Text] [Related]
20. Effects of formoterol on exercise tolerance in severely disabled patients with COPD.
Neder JA; Fuld JP; Overend T; Thirlwell J; Carter R; Stevenson R; Ward SA
Respir Med; 2007 Oct; 101(10):2056-64. PubMed ID: 17658249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
